Increasing ability of early breast cancer (BC) diagnosis leading to more early stage detection, better survival, and low relapse marks one of the milestones achieved over the decades. Foregoing poses a challenge for clinicians regarding optimal treatment, in which over- and under-treatment should be avoided. Classical prognostic and predictive factors fall short for individualized adjuvant therapy selection in this patient group. The key to better characterization may be found in the biology underlying individual tumors. We hypothesized that markers related to cellular proliferation and apoptosis and the balance between these two processes in tumor development will be predictive for clinical outcome. Our study population (N = 822) consisted of all early stage BC patients primarily treated with surgery in our center between 1985 and 1996. Sections of available tumor tissue (87 %, 714/822) were immunohistochemically stained for expression of p53, active-caspase-3, and Ki67. In 43 % (304/714) and 18 % (126/714) of this cohort, respectively, a biochemical C2P® risk prediction and caspase-3 assay were performed. Expression data of the mentioned markers, single, or combined, were analyzed. Results showed that both the single and combined markers, whether of apoptotic or proliferative origin had associations with clinical outcome. An additive effect was seen for the hazard ratios when data on p53, active caspase-3, and Ki67 status were combined. The assembled prognostic apoptotic–proliferative subtype showed significant association for both the overall survival (p = 0.024) and relapse-free period (p = 0.001) in the multivariate analyses of grade I breast tumors. Combined markers of tumor cell apoptosis and proliferation represent tumor aggressiveness. The apoptotic–proliferative subtypes that we present in this study represent a clinical prognostic profile with solid underlying biological rationale and pose a promising method for accurate identification of grade I BC patients in need of an aggressive therapeutic approach, thus contributing to precision medicine in BC disease.
Breast cancer Apoptosis Proliferation Subtypes
This is a preview of subscription content, log in to check access
Research support: Dutch Cancer Society (KWF 2007-3968).
None of the authors who contributed to this article has any financial or personal relationships with people or organizations that could inappropriately influence the data published.
Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17:R245–R262PubMedCrossRefGoogle Scholar
O’Donovan N, Crown J, Stunell H et al (2003) Caspase 3 in breast cancer. Clin Cancer Res 9:738–742PubMedGoogle Scholar
Gong P, Wang Y, Liu G, Zhang J, Wang Z (2013) New insight into Ki67 expression at the invasive front in breast cancer. PLoS ONE 8:e54912PubMedCrossRefGoogle Scholar
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235PubMedCrossRefGoogle Scholar
van Nes JG, de Kruijf EM, Faratian D et al (2011) COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 125:671–685PubMedCrossRefGoogle Scholar
de Kruijf EM, van Nes JG, Sajet A et al (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16:1272–1280PubMedCrossRefGoogle Scholar
Nout RA, Bosse T, Creutzberg CL et al (2012) Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/beta-catenin and P53 pathway activation. Gynecol Oncol 126:466–473PubMedCrossRefGoogle Scholar
Kim SJ, Nakayama S, Shimazu K et al (2012) Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers. Ann Oncol 23:891–897PubMedCrossRefGoogle Scholar
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRefGoogle Scholar
Nyiraneza C, Jouret-Mourin A, Kartheuser A et al (2011) Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer. Hum Pathol 42:1897–1910PubMedCrossRefGoogle Scholar
van Nes JG, Smit VT, Putter H et al (2009) Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients. Br J Cancer 100:494–500PubMedCrossRefGoogle Scholar
Jager JJ, Jansen RL, Arends JW (2002) Clinical relevance of apoptotic markers in breast cancer not yet clear. Apoptosis 7:361–365PubMedCrossRefGoogle Scholar
Oh YL, Choi JS, Song SY et al (2001) Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int 51:94–99PubMedCrossRefGoogle Scholar
Ross JS, Linette GP, Stec J et al (2003) Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 3:573–585PubMedCrossRefGoogle Scholar
Parton M, Krajewski S, Smith I et al (2002) Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. Clin Cancer Res 8:2100–2108PubMedGoogle Scholar
Zeestraten EC, Maak M, Shibayama M et al (2012) Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer 106:133–140PubMedCrossRefGoogle Scholar
Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302:1685–1692PubMedCrossRefGoogle Scholar